Contribute Try STAT+ Today

Top of the morning to you, and a fine one it is. Despite gray skies and a bit of a drizzle, our spirits are sunny today. And why not? As the Morning Mayor taught us: Every day should be unwrapped like a precious gift. So while you tug on the ribbon, we will brew a cup of stimulation and forage for a few interesting items. Speaking of which, here is the latest batch of tidbits to get you started on your journey. We hope all goes well today and you exceed your to-do list. Stay in touch, and stay safe. …

For those closely watching the development of Covid-19 vaccines, Thursday is a crucial date, STAT tells us. Nothing extraordinary is expected to happen when a committee of outside experts — known as the Vaccines and Related Biological Products Advisory Committee, or VRBPAC — meets for the first time to consider Covid-19 vaccines. But the meeting itself is a reassuring sign the Food and Drug Administration, which relies on VRBPAC for advice, plans to do what it usually does: Make decisions based not on political timetables but on data that show whether new vaccines are safe and effective.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Endo’s action follows quite a number of commercials running over the last 6 months (?) for those two conditions I was previously unaware of. One may assume the advertising has worked well.

Comments are closed.

Your daily dose of news in health and medicine

Privacy Policy